Science News
from research organizations

Genetics of melanoma chemoresistance

Date:
June 5, 2011
Source:
Cold Spring Harbor Laboratory
Summary:
Malignant melanoma is a highly aggressive and notoriously chemoresistant form of cancer. In a new paper, researchers reveal that anti-melanoma drugs may, paradoxically, induce a senescence-associated secretory profile ("secretome") that can ultimately promote metastasis and contribute to melanoma relapse.
Share:
       
FULL STORY

Malignant melanoma is a highly aggressive and notoriously chemoresistant form of cancer. In a paper published in Genes & Development, Ohanna et al. reveal that anti-melanoma drugs may, paradoxically, induce a senescence-associated secretory profile ("secretome") that can ultimately promote metastasis and contribute to melanoma relapse.

While cellular senescence has been thought of as a natural mechanism to combat uncontrolled cell growth, or cancer, recent studies have shown that some cell types express a secretome during senescence that alters the tumor microenvironment and affects the cell's response to chemotherapeutic drugs. Ohanna et al. confirm that senescent melanoma cells do, in fact, express an inflammatory secretome, and have delineated the genetic pathways involved: Depletion of the MITF transcription factor, or exposure to anti-melanoma drugs, activates the DNA damage response and triggers senescence. Senescent melanoma cells express a PARP-1 and NF-kB -- associated secretome, which contains high levels of the chemokine CCL2. CCL2, in turn, leads to a loss of E-cadherin expression and an invasive phenotype.

In fact, Ohanna et al. show that culturing melanoma cells with exogenous CCL2 enhances their survival and invasiveness. This finding suggests that blocking CCL2, or its upstream effectors, may represent a novel therapeutic pathway.

As Dr. Bertolotto explains, "Our data disclose a part of the mechanisms contributory to failure of anti-melanoma chemotherapies and we gain valuable insight for the identification of new candidates, namely PARP-1, NF-kB or CCL2, for therapeutic intervention in view to overcome drug resistance."


Story Source:

The above post is reprinted from materials provided by Cold Spring Harbor Laboratory. Note: Materials may be edited for content and length.


Journal Reference:

  1. Mickael Ohanna, Sandy Giuliano, Caroline Bonet, Veronique Imbert, Veronique Hofman, Josephine Zangari, Karine Bille, Caroline Robert, Brigitte Bressac-de Paillerets, Paul Hofman, Stephane Rocchi, Jean-Francois Peyron, Jean-Philippe Lacour, Robert Ballotti and Corine Bertolotto. Senescent cells develop a PARP-1 and Nuclear Factor-kappa B-associated secretome (PNAS). Genes & Development, 2011; 25 (12) [link]

Cite This Page:

Cold Spring Harbor Laboratory. "Genetics of melanoma chemoresistance." ScienceDaily. ScienceDaily, 5 June 2011. <www.sciencedaily.com/releases/2011/06/110605191506.htm>.
Cold Spring Harbor Laboratory. (2011, June 5). Genetics of melanoma chemoresistance. ScienceDaily. Retrieved July 31, 2015 from www.sciencedaily.com/releases/2011/06/110605191506.htm
Cold Spring Harbor Laboratory. "Genetics of melanoma chemoresistance." ScienceDaily. www.sciencedaily.com/releases/2011/06/110605191506.htm (accessed July 31, 2015).

Share This Page: